BLMH
Description
The BLMH (bleomycin hydrolase) is a protein-coding gene located on chromosome 17.
Bleomycin hydrolase is an enzyme encoded by the BLMH gene in humans. This enzyme is a cytoplasmic cysteine peptidase that is highly conserved throughout evolution. Its primary biological role is to hydrolyze the reactive electrophile homocysteine thiolactone. Additionally, it plays a crucial role in detoxifying the glycopeptide bleomycin (BLM), a drug used in cancer chemotherapy. Bleomycin hydrolase inactivates BLM by hydrolyzing its carboxamide bond, thereby protecting cells from BLM's toxic effects. It contains the signature active site residues of the cysteine protease papain superfamily.
Bleomycin hydrolase has been shown to interact with various proteins including RPL29, RPL11, UBE2I, and Amyloid precursor protein.
Bleomycin hydrolase (BMH) is an enzyme that detoxifies the antitumor drug bleomycin (BLM) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety. This prevents BLM from damaging both normal and cancerous cells.
BLMH is also known as BH, BMH.
Associated Diseases
- epidermolytic ichthyosis
- familial reactive perforating collagenosis
- peeling skin syndrome 6
- ulerythema ophryogenesis
- psoriasis 2
- erythrokeratodermia variabilis
- seborrhea-like dermatitis with psoriasiform elements
- immunodeficiency 51
- diffuse nonepidermolytic palmoplantar keratoderma
- verrucous hemangioma
